<DOC>
	<DOC>NCT01657448</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of the combination of Methenamine + Methylthioninium chloride compared to phenazopyridine (comparator product) in the symptomatic relief of dysuria.</brief_summary>
	<brief_title>Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria</brief_title>
	<detailed_description>- Single blind, randomized, prospective study. - Length of experience: 03 days to 07 days. - 03 visits (days 1, 4 and 7). - Evaluation of the efficacy and safety of the medication. - Shall be assessed for adverse events.</detailed_description>
	<mesh_term>Dysuria</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<mesh_term>Methenamine</mesh_term>
	<mesh_term>Methenamine hippurate</mesh_term>
	<criteria>Patients who agree to participate by agreeing to the terms proposed in the Clinical trial; Patients aged over 18 years of any ethnicity; Presence of dysuria with marking greater than or equal to 5 measured points on the categorical scale pretreatment for pain symptom; Patients who are febrile (axillary T º: ≥ 38 ° C), with back pain or lumbar; Patients with complicated clinical presentation of urinary tract infection; Patients with a history of allergy or intolerance to any known or suspected one of the ingredients of the product under investigation; Patients who are pregnant or during lactation, or childbearing potential and are not making use of effective contraception; Patients presenting with renal disease or severe liver disease, according to medical history and / or laboratory; Patients presenting with severe systemic disease according to the known medical history; Patients who received antibiotic treatment, anthelmintic within 7 days prior to study entry; Patients unable to understand the guidelines specified in this protocol or can not attend all study visits or unable to complete the log; Pregnancy or risk of pregnancy and lactating patients; Any finding of clinical observation (history and physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Symptom of Dysuria</keyword>
</DOC>